Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP219594.RAWJQ_m3C9awbovRpwwq9CCG1_dNVd7JrJBLaAleWx5Xc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP219594.RAWJQ_m3C9awbovRpwwq9CCG1_dNVd7JrJBLaAleWx5Xc130_assertion type Assertion NP219594.RAWJQ_m3C9awbovRpwwq9CCG1_dNVd7JrJBLaAleWx5Xc130_head.
- NP219594.RAWJQ_m3C9awbovRpwwq9CCG1_dNVd7JrJBLaAleWx5Xc130_assertion description "[These findings suggest that concomitant PLK1 and HDAC inhibition is active against imatinib mesylate-sensitive or refractory CML and ALL cells both in vitro and in vivo and that this strategy warrants further evaluation in the setting of BCR/ABL(+) leukemias.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP219594.RAWJQ_m3C9awbovRpwwq9CCG1_dNVd7JrJBLaAleWx5Xc130_provenance.
- NP219594.RAWJQ_m3C9awbovRpwwq9CCG1_dNVd7JrJBLaAleWx5Xc130_assertion evidence source_evidence_literature NP219594.RAWJQ_m3C9awbovRpwwq9CCG1_dNVd7JrJBLaAleWx5Xc130_provenance.
- NP219594.RAWJQ_m3C9awbovRpwwq9CCG1_dNVd7JrJBLaAleWx5Xc130_assertion SIO_000772 23204129 NP219594.RAWJQ_m3C9awbovRpwwq9CCG1_dNVd7JrJBLaAleWx5Xc130_provenance.
- NP219594.RAWJQ_m3C9awbovRpwwq9CCG1_dNVd7JrJBLaAleWx5Xc130_assertion wasDerivedFrom befree-20150227 NP219594.RAWJQ_m3C9awbovRpwwq9CCG1_dNVd7JrJBLaAleWx5Xc130_provenance.
- NP219594.RAWJQ_m3C9awbovRpwwq9CCG1_dNVd7JrJBLaAleWx5Xc130_assertion wasGeneratedBy ECO_0000203 NP219594.RAWJQ_m3C9awbovRpwwq9CCG1_dNVd7JrJBLaAleWx5Xc130_provenance.